未明确提及具体用途,主要作为中间体或原料用于医药相关合成(基于参考文献推测)。
医药
合成路线 1(1. 合成:4541-15-5)
产率:89%
合成条件:Stage #1: With sodium hydride In N,N-dimethyl-formamide; mineral oil at 20℃; for 1 h; Stage #2: at 20℃; for 2 h;
实验步骤:向搅拌的60%NaH在矿物油(2.30g,57.69mmol)中的分散体的悬浮液中缓慢加入1,5-戊二醇9(5.0g,48.07mmol)在无水DMF(150mL)中的溶液,历时15分钟。最低温度为0°C。然后将反应混合物在室温下搅拌1小时,然后在15分钟内加入苄基溴(5.75mL,48.07mmol)并在相同温度下再搅拌2小时。用冰冷的水淬灭反应混合物。将粗混合物用乙酸乙酯(2×30mL)萃取,将有机层用盐水洗涤(3次),用无水Na 2 SO 4干燥,并在真空下浓缩。残留物经硅胶柱层析纯化,用石油醚 - 乙酸乙酯(7:3)作洗脱液,得到苄基醚10.产量:89%(7.87g),无色油状物; IR(CHCl3,cm-1):υmax700,714,1028,1072,1116,1177,1278,1316,1388,1453,2865,2938,3064,3332; 1H NMR(200MHz,CDCl3):δ1.47-1.70(m,6H),3.47(t,J = 6.3Hz,2H),3.62(t,J = 6.1Hz,2H),4.49(s,2H), 7.31(s,5H); 13C NMR(50MHz,CDCl3):δ22.3,29.3,32.3,62.2,70.2,72.8,127.5,128.2,138.3; HRMS(ESI):计算值。 [(C 12 H 18 O 2)H](M + H)195.1385,实测值195.1390。
参考文献:
- [1] Journal of the American Chemical Society, 2007, vol. 129, # 5, p. 1465 - 1469 [2] Organic Letters, 2016, vol. 18, # 7, p. 1622 - 1625 [3] Journal of the American Chemical Society, 2015, vol. 137, # 1, p. 420 - 424 [4] Tetrahedron Letters, 2016, vol. 57, # 1, p. 25 - 28 [5] Helvetica Chimica Acta, 2015, vol. 98, # 10, p. 1395 - 1402 [6] Journal of Organic Chemistry, 1995, vol. 60, # 10, p. 2989 - 2999 [7] Tetrahedron, 2009, vol. 65, # 33, p. 6470 - 6488 [8] Journal of Organic Chemistry, 2007, vol. 72, # 4, p. 1104 - 1111 [9] Journal of Medicinal Chemistry, 2011, vol. 54, # 7, p. 2069 - 2079 [10] Chemical Communications, 2006, # 36, p. 3783 - 3785 [11] Tetrahedron, 2005, vol. 61, # 47, p. 11132 - 11140 [12] Tetrahedron Asymmetry, 2004, vol. 15, # 3, p. 565 - 570 [13] Organic Letters, 2004, vol. 6, # 21, p. 3849 - 3852 [14] Tetrahedron, 2010, vol. 66, # 17, p. 3265 - 3274 [15] Synthesis, 2012, vol. 44, # 3, p. 469 - 473 [16] Synlett, 2015, vol. 26, # 7, p. 937 - 941 [17] European Journal of Organic Chemistry, 2012, # 6, p. 1253 - 1258 [18] Journal of Medicinal Chemistry, 2004, vol. 47, # 16, p. 3938 - 3948 [19] Journal of Organic Chemistry, 2010, vol. 75, # 23, p. 8307 - 8310 [20] Synthesis, 2012, vol. 44, # 4, p. 585 - 590 [21] Advanced Synthesis and Catalysis, 2013, vol. 355, # 13, p. 2591 - 2603 [22] Tetrahedron Letters, 2014, vol. 55, # 52, p. 7177 - 7180 [23] Bioorganic Chemistry, 2009, vol. 37, # 2, p. 46 - 51 [24] Patent: WO2018/189554, 2018, A1. Location in patent: Page/Page column 52 [25] Journal of Organic Chemistry, 2000, vol. 65, # 16, p. 4833 - 4838 [26] Journal of Organic Chemistry, 2008, vol. 73, # 13, p. 5198 - 5201 [27] Synthetic Communications, 2013, vol. 43, # 10, p. 1397 - 1403 [28] Journal of Fluorine Chemistry, 2015, vol. 178, p. 47 - 55 [29] Tetrahedron Letters, 2005, vol. 46, # 23, p. 4023 - 4026 [30] Patent: US2016/2164, 2016, A1. Location in patent: Paragraph 0114-0116 [31] Organic Letters, 2009, vol. 11, # 15, p. 3270 - 3273 [32] Heterocycles, 2012, vol. 86, # 1, p. 565 - 598 [33] Journal of Medicinal Chemistry, 2013, vol. 56, # 12, p. 5033 - 5047 [34] Patent: WO2018/119441, 2018, A1. Location in patent: Paragraph 00590 [35] Journal of the American Chemical Society, 2009, vol. 131, # 42, p. 15467 - 15473 [36] Tetrahedron, 2005, vol. 61, # 6, p. 1459 - 1480 [37] Journal of Organic Chemistry, 1971, vol. 36, p. 3526 - 3532 [38] Journal of the American Chemical Society, 1990, vol. 112, # 8, p. 3040 - 3054 [39] Tetrahedron Letters, 1985, vol. 26, # 41, p. 5053 - 5056 [40] Canadian Journal of Chemistry, 1994, vol. 72, # 6, p. 1500 - 1511 [41] Liebigs Annalen, 1995, # 6, p. 965 - 978 [42] Journal of the Chinese Chemical Society, 2002, vol. 49, # 6, p. 1079 - 1088 [43] Tetrahedron, 2003, vol. 59, # 38, p. 7547 - 7553 [44] Tetrahedron Letters, 2006, vol. 47, # 34, p. 6121 - 6123 [45] Organic and Biomolecular Chemistry, 2007, vol. 5, # 16, p. 2678 - 2689 [46] Patent: US2003/69434, 2003, A1 [47] Patent: US5081287, 1992, A [48] Canadian Journal of Chemistry, 2010, vol. 88, # 12, p. 1222 - 1232 [49] Journal of the American Chemical Society, 2012, vol. 134, # 16, p. 6976 - 6979 [50] Tetrahedron Letters, 2013, vol. 54, # 42, p. 5758 - 5760 [51] Patent: US2013/331578, 2013, A1. Location in patent: Paragraph 0099-0100